Buchumschlag

The PAZOREAL noninterventional study to assess effectiveness and safety of pazopanib and everolimus in the changing metastatic renal cell carcinoma treatment landscape

VEGFR and mTOR inhibitors are broadly used in metastatic renal cell carcinoma (mRCC) therapy, and sequential first-line pazopanib (VEGFR inhibitor) and second-line everolimus (mTOR inhibitor) is a standard treatment option. Nivolumab and lenvatinib/everolimus combination was recently approved in Eur...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Goebell, Peter Jürgen (VerfasserIn) , Grüllich, Carsten (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 19 May 2017
In: Future oncology
Year: 2017, Jahrgang: 13, Heft: 17, Pages: 1463-1471
ISSN:1744-8301
DOI:10.2217/fon-2017-0083
Online-Zugang:Verlag, Volltext: http://dx.doi.org/10.2217/fon-2017-0083
Verlag, Volltext: https://www.futuremedicine.com/doi/10.2217/fon-2017-0083
Volltext
Verfasserangaben:Peter J Goebell, Christian Doehn, Carsten Grüllich, Viktor Grünwald, Thomas Steiner, Rainer Ehneß & Manfred Welslau

MARC

LEADER 00000caa a2200000 c 4500
001 158075905X
003 DE-627
005 20220815003302.0
007 cr uuu---uuuuu
008 180907s2017 xx |||||o 00| ||eng c
024 7 |a 10.2217/fon-2017-0083  |2 doi 
035 |a (DE-627)158075905X 
035 |a (DE-576)51075905X 
035 |a (DE-599)BSZ51075905X 
035 |a (OCoLC)1341018170 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Goebell, Peter Jürgen  |d 1967-  |e VerfasserIn  |0 (DE-588)12273064X  |0 (DE-627)706018834  |0 (DE-576)293397899  |4 aut 
245 1 4 |a The PAZOREAL noninterventional study to assess effectiveness and safety of pazopanib and everolimus in the changing metastatic renal cell carcinoma treatment landscape  |c Peter J Goebell, Christian Doehn, Carsten Grüllich, Viktor Grünwald, Thomas Steiner, Rainer Ehneß & Manfred Welslau 
264 1 |c 19 May 2017 
300 |a 9 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 07.09.2018 
520 |a VEGFR and mTOR inhibitors are broadly used in metastatic renal cell carcinoma (mRCC) therapy, and sequential first-line pazopanib (VEGFR inhibitor) and second-line everolimus (mTOR inhibitor) is a standard treatment option. Nivolumab and lenvatinib/everolimus combination was recently approved in Europe for use in mRCC after previous therapy. Prospective routine data on sequential therapy including nivolumab and/or lenvatinib are missing. This is a prospective, noninterventional study, which evaluates the effectiveness, tolerability, safety and quality of life following 450 patients with mRCC starting either on pazopanib as first-line therapy or third-line everolimus plus/minus lenvatinib following nivolumab. Adults with histologically confirmed mRCC of any subtype, who have a life expectancy of at least 6 months, are eligible. 
700 1 |a Grüllich, Carsten  |d 1965-  |e VerfasserIn  |0 (DE-588)14101914X  |0 (DE-627)624500985  |0 (DE-576)321797981  |4 aut 
773 0 8 |i Enthalten in  |t Future oncology  |d London : Taylor & Francis, 2005  |g 13(2017), 17, Seite 1463-1471  |h Online-Ressource  |w (DE-627)484405055  |w (DE-600)2184533-5  |w (DE-576)398100217  |x 1744-8301  |7 nnas  |a The PAZOREAL noninterventional study to assess effectiveness and safety of pazopanib and everolimus in the changing metastatic renal cell carcinoma treatment landscape 
773 1 8 |g volume:13  |g year:2017  |g number:17  |g pages:1463-1471  |g extent:9  |a The PAZOREAL noninterventional study to assess effectiveness and safety of pazopanib and everolimus in the changing metastatic renal cell carcinoma treatment landscape 
856 4 0 |u http://dx.doi.org/10.2217/fon-2017-0083  |x Verlag  |x Resolving-System  |3 Volltext 
856 4 0 |u https://www.futuremedicine.com/doi/10.2217/fon-2017-0083  |x Verlag  |3 Volltext 
951 |a AR 
992 |a 20180907 
993 |a Article 
994 |a 2017 
998 |g 14101914X  |a Grüllich, Carsten  |m 14101914X:Grüllich, Carsten  |d 910000  |e 910000PG14101914X  |k 0/910000/  |p 5 
999 |a KXP-PPN158075905X  |e 3024871594 
BIB |a Y 
SER |a journal 
JSO |a {"relHost":[{"title":[{"title_sort":"Future oncology","title":"Future oncology"}],"note":["Gesehen am 28.05.2024"],"type":{"bibl":"periodical","media":"Online-Ressource"},"pubHistory":["1.2005 -"],"language":["eng"],"physDesc":[{"extent":"Online-Ressource"}],"origin":[{"dateIssuedDisp":"2005-","dateIssuedKey":"2005","publisher":"Taylor & Francis ; Future Medicine Ltd","publisherPlace":"London ; London"}],"id":{"eki":["484405055"],"issn":["1744-8301"],"zdb":["2184533-5"]},"part":{"year":"2017","issue":"17","text":"13(2017), 17, Seite 1463-1471","extent":"9","volume":"13","pages":"1463-1471"},"recId":"484405055","disp":"The PAZOREAL noninterventional study to assess effectiveness and safety of pazopanib and everolimus in the changing metastatic renal cell carcinoma treatment landscapeFuture oncology"}],"note":["Gesehen am 07.09.2018"],"name":{"displayForm":["Peter J Goebell, Christian Doehn, Carsten Grüllich, Viktor Grünwald, Thomas Steiner, Rainer Ehneß & Manfred Welslau"]},"recId":"158075905X","id":{"eki":["158075905X"],"doi":["10.2217/fon-2017-0083"]},"origin":[{"dateIssuedDisp":"19 May 2017","dateIssuedKey":"2017"}],"language":["eng"],"physDesc":[{"extent":"9 S."}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"person":[{"given":"Peter Jürgen","role":"aut","family":"Goebell","display":"Goebell, Peter Jürgen"},{"display":"Grüllich, Carsten","given":"Carsten","role":"aut","family":"Grüllich"}],"title":[{"title":"The PAZOREAL noninterventional study to assess effectiveness and safety of pazopanib and everolimus in the changing metastatic renal cell carcinoma treatment landscape","title_sort":"PAZOREAL noninterventional study to assess effectiveness and safety of pazopanib and everolimus in the changing metastatic renal cell carcinoma treatment landscape"}]} 
SRT |a GOEBELLPETPAZOREALNO1920 

Ähnliche Einträge